Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karen Boyd

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Clinical Child Psychology and Psychiatry|August 20, 2011
Parents of adolescents who have committed sexual offenses: characteristics, challenges, and interventionsKaren Boyd Worley, Janice K Church, John C Clemmons
The Oncologist|May 29, 2014
U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutationsSean Khozin, Gideon M Blumenthal, Xiaoping Jiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2015
FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancerSean Khozin, Gideon M Blumenthal, Lijun Zhang, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Clinical Child Psychology and Psychiatry|August 20, 2011
Parents of adolescents who have committed sexual offenses: characteristics, challenges, and interventionsKaren Boyd Worley, Janice K Church, John C Clemmons
The Oncologist|May 29, 2014
U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutationsSean Khozin, Gideon M Blumenthal, Xiaoping Jiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2015
FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancerSean Khozin, Gideon M Blumenthal, Lijun Zhang, et al.
Pageof 1